This fully cGMP-compliant single-use bioreactor is developed for clinical trial material preparation and commercial biomanufacturing of monoclonal antibodies, viral vectors, cell therapies and recombinant proteins. Every component of the disposable fluid contact path is manufactured under controlled cleanroom conditions, with complete material certification, extractables & leachables (E&L) test reports and full batch traceability available for regulatory inspections.
Free from repeated CIP/SIP cleaning cycles and lengthy cleaning validation activities, the closed single-use system fundamentally eliminates cross-contamination and batch carryover risks between different products or production runs. Optimised low-shear mixing design safeguards sensitive suspension cells, while integrated automated control of temperature, pH, dissolved oxygen, agitation and gas overlay delivers stable and reproducible culture performance batch to batch.
Fully aligned with FDA, EMA and ISO biomanufacturing standards, the control system features complete audit trails, electronic signature support and data integrity complying with 21 CFR Part 11. Scalable from lab process development volumes all the way to full commercial production scale, it drastically cuts cleanroom infrastructure investment and production turnaround time, enabling biopharma enterprises and CDMOs to accelerate pipeline advancement while staying fully regulatory compliant.
